Clinical trials: Gonadotropins
Endocrine Disease, Infertility
Hormonal Regulation of Puberty and Fertility
Background: The body produces gonadotropin-releasing hormone (GnRH) about every 2 hours. GnRH travels through the bloodstream to the pituitary gland, where it stimulates the gland to produce hormones called gonadotropins.
- Conditions
- Endocrine Disease, Infertility, Hypogonadism, Amenorrhea
- Trial name
- NCT01511588
- Where
- 2 sites in United States
- Volunteers
- 111 people
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Kallmann Syndrome, Hypogonadotropic Hypogonadism
Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)
The purpose of the study is to examine how Kallmann syndrome (KS) and idiopathic hypogonadotropic hypogonadism (IHH) affect reproductive hormones.
- Conditions
- Kallmann Syndrome, Hypogonadotropic Hypogonadism, GnRH Deficiency
- Trial name
- NCT00392756
- Testing
- gonadotropin releasing hormone (GnRH)
- Where
- United States
- Volunteers
- 624 people
- Sponsor
- Massachusetts General Hospital
Precocious Puberty, Central
Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty
This study determines the effectiveness of leuprolide acetate 45 mg for injectable suspension for treatment of children with Central Precocious Puberty.
- Trial name
- NCT02452931
- Testing
- Leuprolide Acetate 45 mg
- Where
- 20 sites in United States, Argentina and 4 more
- Volunteers
- 64 people
- Sponsor
- Tolmar Inc.
Abortion Early
Point of Care Tests in the Management of Very Early Medical Abortion
This study will investigate the use of a point of care test in patients who are having an abortion at a gestation of <6 weeks (known as a very early medical abortion).
- Trial name
- POCT VEMA (NCT07417787)
- Testing
- Blood test, Participant Questionnaire
- Where
- 3 sites in Sweden, United Kingdom
- Volunteers
- 130 people
- Sponsor
- University of Edinburgh
Idiopathic Hypogonadotropic Hypogonadism
Efficacy and Safety of Pulsatile Gonadotropin Releasing Hormone Pump Treatment in Patients With Idiopathic Hypogonadotropic Hypogonadism
Idiopathic hypogonadotropic hypogonadism (IHH) is the most common disorders of sex development (DSD).Therapy for IHH includes hormone replacement therapy, gonadotropin therapy and pulsed infusion of gonadotropin releasing hormone…
- Trial name
- NCT02310074
- Testing
- Pulsatile Gonadotropin Releasing Hormone, Human chorionic gonadotropin, Urinary Follicle-Stimulating Hormone
- Volunteers
- 76 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Puberty, Precocious
Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]
The primary objective of this study is to investigate whether bicalutamide given in combination with anastrozole once daily for 12 months is effective in treating testotoxicosis in boys.
- Trial name
- BATT (NCT00094328)
- Testing
- Bicalutamide, Anastrozole
- Where
- 15 sites in United States, Canada and 4 more
- Volunteers
- 14 people
- Sponsor
- AstraZeneca
Hypogonadotropic Hypogonadism
Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043)
The purpose of the study is to investigate whether corifollitropin alfa (MK-8962), administered alone for 12 weeks and then in combination with human chorionic gonadotropin (hCG) for 52 weeks, increases the testicular volume in…
- Trial name
- NCT03019575
- Testing
- Corifollitropin alfa, hCG
- Where
- 15 sites in Brazil, Denmark and 4 more
- Volunteers
- 17 people
- Sponsor
- Organon and Co
Down Syndrome, Chromosome Abnormalities
Down Syndrome - Comparison of Screening Methods in the 1st and 2nd Trimesters
Too much or too little genetic information (chromosome material) can cause abnormal development of the fetus or death. Each year approximately 2.5 million pregnant women are screened for Down Syndrome using invasive screening…
- Trial name
- NCT00006445
- Testing
- Ultrasound, Serum screen
- Where
- 10 sites in United States
- Volunteers
- 38,000 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Infertility
Frozen Embryo Transfer (FET) in Natural Cycles or in Natural Cycles Controlled by Human Chorionic Gonadotropin (hCG) Administration
The rational of the study is to assess the implantation, pregnancy and live birth rates after the transfer of frozen- thawed embryos in natural cycles with spontaneous Luteinizing Hormone (LH)/Progesterone rise or in natural…
- Trial name
- FRET (NCT00809107)
- Testing
- HCG
- Where
- Belgium
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Acute-graft-versus-host Disease
Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids
This multi-center center phase I/II study to establish the lowest possible recommended phase 2 dose (RP2D) of corticosteroids in conjunction with ruxolitinib and uhCG/EGF (a novel combination) for high-risk aGVHD.
- Trial name
- NCT05123040
- Testing
- Ruxolitinib 10 MG Oral Tablet, hCG, Corticosteroids
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Controlled Ovarian Hyperstimulation, Polycystic Ovarian Syndrome
Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist Protocols in Women With Polycystic Ovarian Syndrome
The purpose of this study is to compare the use of the progesterone-primed ovarian stimulation protocol versus GnRH antagonist protocol in women with polycystic ovarian syndrome (PCOS) regarding the number of oocytes retrieved…
- Trial name
- NCT06812559
- Testing
- Progesterone, GnRH antagonist (Cetrorelix)
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- El Shatby University Hospital for Obstetrics and Gynecology
Infertility
Agonist Gonadotropin-Releasing Hormone (GnRH) Versus Antagonist GnRH
Literature suggests that GnRH antagonists are comparatively more often used in cycles which have an unfavorable prior prognosis, and this protocol is an ideal one for poor responder patients.
- Trial name
- NCT00823602
- Testing
- ganirelix, suprefact
- Where
- Iran
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Yazd Research & Clinical Center for Infertility
Infertility
Programming by Estrogen Treatment in Gonadotropin Releasing Hormone Antagonist Protocol
The purpose of this study is to determine if pretreatment with Estrogen can assist in the planning and programming of In Vitro Fertilization treatments.
- Trial name
- NCT01419353
- Testing
- estradiol valerate
- Where
- Israel
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Meir Medical Center
Precocious, Leuprolide Acetate
Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty
The purpose of this extension study is to determine if leuprolide acetate (11.25 mg and 30 mg) is safe in treating children with Central Precocious Puberty over a longer period of time (36 months).
- Conditions
- Precocious, Leuprolide Acetate, Luteinizing Hormone (LH), Gonadotrophin-releasing Hormone Agonist (GnRHa)
- Trial name
- NCT00667446
- Testing
- Leuprolide Acetate 3 Month Depot
- Where
- 20 sites in United States, Puerto Rico
- Volunteers
- 72 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
APHRODITE Group
Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive
The goal of this clinical trial is to determine whether short-term gonadotropin therapy (hCG + FSH) can increase sperm availability for ICSI in men with idiopathic non-obstructive azoospermia (NOA) and hypogonadism.
- Trial name
- GTIHNO (NCT07540611)
- Testing
- No intervention, hCG + FSH therapy
- Where
- 8 sites in India
- Volunteers
- 860 people, healthy volunteers welcome
- Sponsor
- Indira IVF Hospital Pvt Ltd
CPP
Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty
This study is a multicenter, open-label, single-group, and phase 4 study to evaluate the efficacy and safety of 45 mg of leuprolide acetate in CPP.
- Trial name
- NEST (NCT06926933)
- Testing
- Eligard® 45 mg
- Where
- 9 sites in South Korea
- Volunteers
- 50 people
- Sponsor
- HanAll BioPharma Co., Ltd.
Infertility and at High Risk of OHSS
Dual Trigger to Reduce Ovarian Hyperstimulation Syndrome
Gonadotropin releasing hormone (GnRH) agonist is sufficient for triggering final oocyte maturation in GnRH antagonist protocol and can significantly reduce incidence of ovarian hyperstimulation syndrome (OHSS) in high-risk…
- Trial name
- NCT02022228
- Testing
- triptorelin, hCG
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chenshiling
Cancer, Chemoradiation
GnRHA Therapy and Ovarian Preservation in Pediatric Cancer Patient
This is a prospective case control study. Participants will be enrolled as case subjects or control subjects, depending upon the gonadotoxicity of their chemoradiation therapy.
- Trial name
- NCT02677311
- Testing
- Blood draw, Pelvic Ultrasound
- Volunteers
- 2 people
- Sponsor
- University of Kentucky
Infertility
An Observational Study of Cetrotide® Gonadotropin-releasing Hormone Antagonist (GnRH Antagonist) With GONAL-f® in Assisted Reproductive Technologies (ART)
This is a multicentric, prospective, observational study on the use of Cetrotide to control the endogenous gonadotrophin levels in Gonal-f stimulated ART treatment cycles in the Asia-Pacific region.
- Trial name
- NCT01109654
- Testing
- Cetrorelix acetate and Follitropin alfa
- Where
- Singapore
- Volunteers
- 2,175 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Prostate Cancer
A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
The purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT)…
- Trial name
- PRONOUNCE (NCT02663908)
- Testing
- Degarelix, Leuprolide
- Where
- 133 sites in United States, Canada and 10 more
- Volunteers
- 545 people
- Sponsor
- Ferring Pharmaceuticals